SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing’s Syndrome

SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing’s Syndrome
Conditions:   Cushing’s Syndrome I;   Cushing Disease Due to Increased ACTH Secretion;   Cortisol Excess;   Cortisol; Hypersecretion;   Cortisol Overproduction;   Ectopic ACTH Secretion
Interventions:   Drug: SPI-62;   Drug: Placebo
Sponsor:   Sparrow Pharmaceuticals
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 2, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments